| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Human leukocyte antigens (HLA) are highly polymorphic gene loci that encode cell-surface glycoproteins which are the strongest transplant antigens leading to T-cell activation, antibody production, and allograft rejection. Personalized iPS cells hold great promise as cellular therapies by autologous transplantation. However, on-demand generation or banking of individualized iPS cells to treat all patients is neither technically nor economically feasible. On the other hand, ‘Universal’ iPS cells which bear no intrinsic HLA signature, would avoid immune rejection. We developed an epigenetic regulation system to control HLA gene expression and presentation. We explored the reversibility of the system with the goal of providing widely applicable and safe iPS cells for regenerative medicine.
|
